

SARS-CoV-2 transmission via endoscopy in the COVID-19 era

We have read with interest the latest paper by Boškoski *et al*¹ on the virological status of reprocessed endoscopes used for critically ill patients during the COVID-19 pandemic.

Proper reprocessing of endoscopes and accessories is essential to patient safety. Although existing data suggest that the risk of viral transmission via endoscopic equipment is extremely low (with virtually no reported cases of hepatitis B and C or HIV transmission following current disinfection guidelines²), the present COVID-19 pandemic has put a spotlight on quality control as a guarantor of patient and healthcare worker safety.

Boškoski *et al* report no evidence of viral contamination of endoscopes in critically ill patients undergoing upper and lower GI endoscopy as well as biliopancreatic procedures (endoscopic ultrasound and endoscopic retrograde cholangiopancreatography). This is in accordance with previous studies suggesting that the risk of fomite transmission of SARS-CoV-2, although plausible,³ remains low.⁴ Endoscopy is regarded as a moderate to

high-risk procedure⁵ due to aerosolisation and contact with infected bodily fluids (sputum, faecal matter and even bile⁶), but linking transmission of SARS-CoV-2 to a previous endoscopic procedure is difficult, considering the large variation in both the incubation and viraemic periods.

The authors did not account for the timing of endoscopy in relation to the moment of infection and/or admission. As shown by recent studies, viral load in patients with COVID-19 decreases substantially over a short period of time,⁷ so even patients in critical condition might, in fact, have low viral loads when admitted to the endoscopy ward. Moreover, there is evidence that supports a rapid decline in infectivity after several days,⁸ independent of viral load,⁹ possibly justifying the lack of infectious isolates from the collected samples. In our own experience, there have been significant delays in access to endoscopy for patients with COVID-19 (data currently under review for publication), and this might, at least in part, account for the results of Boškosi *et al.* The findings of the study are reassuring, and we would like to point out that, even positive PCR findings would still not be enough to confirm infectivity since viral viability should be demonstrated by means of culture rather than PCR.

Due to the significant impact of the SARS-CoV-2 on patient care, in-depth studies to establish clear correlations between viral load, infectivity and transmission risks are required to provide definitive answers in this matter.

Theodor Alexandru Voiosu,^{1,2}

Claudia Irina Puscasu ,¹ **Andrei Voiosu**^{1,2}

¹Gastroenterology, Colentina Clinical Hospital, Bucharest, Romania

²Internal Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

Correspondence to Dr Claudia Irina Puscasu, Gastroenterology, Spitalul Clinic Colentina, Bucuresti 020125, Romania; puscasu_ic@yahoo.com

Contributors TAV conceptualised the article. TAV, AV and CIP were equally involved in manuscript drafting, critical revision of the article for important intellectual content and final approval.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download

and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Voiosu TA, Puscasu CI, Voiosu A. *Gut* 2021;**70**:2218–2219.

Received 1 February 2021

Revised 27 February 2021

Accepted 1 March 2021

Published Online First 5 March 2021

Gut 2021;**70**:2218–2219. doi:10.1136/gutjnl-2021-324276

ORCID iD

Claudia Irina Puscasu <http://orcid.org/0000-0001-6316-2080>

REFERENCES

- Boškosi I, Di Gemma A, Matteo MV, *et al.* Endoscopes used in positive and critically ill patients are SARS-CoV-2 negative at virological assessment. *Gut* 2021;70:1629–31.
- ASGE Quality Assurance in Endoscopy Committee, Calderwood AH, Day LW, *et al.* ASGE guideline for infection control during GI endoscopy. *Gastrointest Endosc* 2018;87:1167–79.
- van Doremalen N, Bushmaker T, Morris DH, *et al.* Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. *N Engl J Med* 2020;382:1564–7.
- Mondelli MU, Colaneri M, Seminari EM, *et al.* Low risk of SARS-CoV-2 transmission by fomites in real-life conditions. *Lancet Infect Dis* 2020. doi:10.1016/S1473-3099(20)30678-2. [Epub ahead of print: 29 Sep 2020].
- Hussain A, Singhal T, EL-Hasani S. Extent of infectious SARS-CoV-2 aerosolisation as a result of oesophagogastroduodenoscopy or colonoscopy. *Br J Hosp Med* 2020;81:1–7.
- Liao Y, Wang B, Wang J, *et al.* SARS-CoV-2 in the bile of a patient with COVID-19-associated gallbladder disease. *Endoscopy* 2020;52:1148.
- Chen P, Nirula A, Heller B, *et al.* SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. *N Engl J Med* 2021;384:229–37.
- He X, Lau EHY, Wu P, *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med* 2020;26:672–5.
- Walsh KA, Jordan K, Clyne B, *et al.* SARS-CoV-2 detection, viral load and infectivity over the course of an infection. *J Infect* 2020;81:357–71.